Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the... see more

Recent & Breaking News (NDAQ:OKUR)

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

GlobeNewswire March 25, 2024

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

GlobeNewswire December 14, 2023

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

GlobeNewswire November 13, 2023

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 2, 2023

Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

GlobeNewswire October 25, 2023

Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

GlobeNewswire October 9, 2023

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

GlobeNewswire October 6, 2023

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire August 29, 2023

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

GlobeNewswire August 10, 2023

Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum

GlobeNewswire June 30, 2023

Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices

GlobeNewswire June 26, 2023

Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023

GlobeNewswire June 15, 2023

Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

Reneo Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 3, 2023

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire May 3, 2023

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 27, 2023

Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies

GlobeNewswire March 14, 2023

Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

GlobeNewswire March 9, 2023

Podcasts